What is Smartlens?
Smartlens Inc is at the forefront of anterior segment disease management, specializing in innovative technologies for remote monitoring and treatment. The company's flagship product, miLens, represents a breakthrough as the world's smallest wearable intraocular pressure (IOP) monitoring device, specifically engineered to address the complexities of glaucoma care. Beyond hardware, the company integrates its Slit IQ AI-powered remote examination platform and the THERx IQ wearable medication management system to create a comprehensive ecosystem for eye health.
By synthesizing advanced artificial intelligence with microfluidic technology, Smartlens provides clinicians and patients with actionable, real-time data. This technological synergy facilitates early detection of ocular disorders and promotes proactive treatment strategies, ultimately aiming to mitigate the risks of irreversible vision loss. The company's market position is defined by its commitment to transforming specialized eye care into a scalable, accessible, and data-rich service model.
How much funding has Smartlens raised?
Smartlens has raised a total of $11.3M across 2 funding rounds:
Series A
$6.1M
Private Equity
$5.2M
Series A (2023): $6.1M with participation from Graphene Ventures, Plaisance Capital, and Sophia Capital
Private Equity (2025): $5.2M, investors not publicly disclosed
Key Investors in Smartlens
Graphene Ventures
Graphene Ventures is a venture capital firm that focuses on early-stage technology companies in the enterprise software and consumer technology sectors, leveraging over 50 years of operational experience.
Plaisance Capital
Plaisance Capital is a Contrarian Value investment firm based in Denver, Colorado, focused on determining the long-term intrinsic value of businesses through a Long/Short portfolio model.
Sophia Capital
Sophia Capital is an economic group specializing in private equity investments in Argentina, utilizing a sector-agnostic, value-investing approach to unlock growth through local expertise.
What's next for Smartlens?
With the successful closure of this major strategic investment, Smartlens is poised to scale its operational infrastructure and expand its global footprint. The company's roadmap likely involves the commercialization of its integrated product suite and the further refinement of its AI algorithms to enhance diagnostic accuracy. As Smartlens moves into this next phase of enterprise-level growth, the focus will shift toward securing broader clinical adoption and establishing strategic partnerships within the healthcare ecosystem to solidify its leadership in the digital ophthalmology market.
The influx of capital provides the necessary runway to navigate regulatory landscapes and invest in R&D, ensuring that Smartlens remains a pioneer in wearable medical devices. Investors are closely watching the company's ability to translate its technological innovations into sustained clinical outcomes and long-term value creation within the competitive landscape of medical technology.
